Harvard Management Company’s Recursion Pharmaceuticals RXRX Stock Holding History

Harvard Management Company’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-882,129	Closed	-$6.59M	–	30
2023 Q2	$6.59M	Sell	882,129 -627,125	-42%	-$4.39M	0.65%	12
2023 Q1	$10.1M	Hold	1,509,254	–	–	1.06%	16
2022 Q4	$11.6M	Hold	1,509,254	–	–	1.44%	8
2022 Q3	$16.1M	Hold	1,509,254	–	–	2%	8
2022 Q2	$12.3M	Hold	1,509,254	–	–	1.42%	9
2022 Q1	$10.8M	Hold	1,509,254	–	–	1.09%	11
2021 Q4	$25.9M	Hold	1,509,254	–	–	2.43%	8
2021 Q3	$34.7M	Hold	1,509,254	–	–	2.04%	9
2021 Q2	$55.1M	Buy	+1,509,254	New	+$44.7M	3.17%	8

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Harvard Management Company's RXRX Position: Q3 2023 in Review

Harvard Management Company sold out of Recursion Pharmaceuticals (RXRX) in Q3 2023, closing a stake of 882,129 shares — an estimated $6.59M sold.

Harvard Management Company first reported a position in RXRX in Q2 2021 and held it in 9 quarters. The position peaked at $55.1M in Q2 2021. 192 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

Harvard Management Company reported no remaining Recursion Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 882,129 Recursion Pharmaceuticals shares in Q3 2023, an estimated $6.59M.
Harvard Management Company first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 9 quarters.
Harvard Management Company's Recursion Pharmaceuticals position peaked at $55.1M in Q2 2021.
192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.